Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Division of Cancer Prevention Staff

Portrait of Worta McCaskill-Stevens, MD, MS

Worta McCaskill-Stevens, MD, MS

Community Oncology and Prevention Trials Research Group
Division of Cancer Prevention
National Cancer Institute
9609 Medical Center Drive, Room 5E446
Rockville, MD 20850
Phone (240) 276-7050
Fax (240) 276-7847
  • Dr. Worta McCaskill-Stevens is a medical oncologist and Chief of the Community Oncology and Prevention Trials Research Group, which houses the Community Clinical Oncology Program (CCOP), Minority-Based CCOP, and the Research Bases for cancer prevention and control clinical trials. After arriving at the NCI in 1998, she became the program director for the Study of Tamoxifen and Raloxifene (STAR), and assumed responsibilities for breast cancer prevention with the CCOP. She chaired the 2009 NIH State-of-the Science Conference on ductal carcinoma in situ; is a member of the Early Breast Cancer Clinical Trialist Group (Oxford, UK); and is a member of NCI’s Breast Cancer Steering Committee.

    After attending Washington University and the American College of Switzerland, she completed medical school and an internal medicine residency at Georgetown University followed by a medical oncology fellowship at the Mayo Clinic (Rochester, MN). Prior to her current position, she was the Co-Director of the Breast Care and Research Center at the Indiana University Cancer Center. Her honors and awards include the Kaiser Family Fund Award for Excellence in Academic Achievement and Leadership in Medicine; Omega Alpha Medical Honor Society; the NIH Director’s Award for Clinical Trials; and the NCI Merit Award for breast cancer prevention. Prior to medical school, Dr. McCaskill-Stevens was a medical editor for Marcel Dekker and the Alan Guttamcher Institute.

  • Cancer disparities research both nationally and internationally

  • Management of comorbidities within clinical trials

  • Molecular research that helps to identify those individuals who will best benefit from cancer prevention interventions

Back to top